EFTR insider filings
eFFECTOR Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-06-13. Screen EFTR transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for EFTR between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — eFFECTOR Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-06-13 | 4 | Harrington-Smith Kristen — Director | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Bhatt Elizabeth — Director | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Gallagher Brian M. Jr. — Director | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Klencke Barbara — Director | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Loewy Caroline M — Director | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Ehrlich Christopher B — Director | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Byrnes Michael — Chief Financial Officer | Grant/award (A): 1,387 @ $1.68 | EDGAR |
| 2024-05-17 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Grant/award (A): 1,806 @ $1.68 | EDGAR |
| 2024-02-21 | 4 | Harrington-Smith Kristen — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Warner Douglas J — Chief Medical Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Bhatt Elizabeth — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Gallagher Brian M. Jr. — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Klencke Barbara — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Byrnes Michael — Chief Financial Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Loewy Caroline M — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Ehrlich Christopher B — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-11-29 | 4 | SR ONE CAPITAL MANAGEMENT, LLC — 10% owner SR One Capital Fund I Aggregator LP — 10% owner SR ONE CAPITAL PARTNERS I, LP — 10% owner SR One Co-Invest I, LLC — 10% owner SR One Co-Invest I Manager, LLC — 10% owner George Simeon — 10% owner | Sale (S): 430,578 @ $0.61 · Sale (S): 178,585 @ $0.61 | EDGAR |
| 2023-11-16 | 4 | Byrnes Michael — Chief Financial Officer | Grant/award (A): 4,524 @ $0.50 | EDGAR |
| 2023-11-16 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Grant/award (A): 5,979 @ $0.50 | EDGAR |
| 2023-09-11 | 4 | Loewy Caroline M — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Option exercise (M): 33,799 @ $0.52 · Option exercise (M): 33,799 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Harrington-Smith Kristen — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Bhatt Elizabeth — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Gallagher Brian M. Jr. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Klencke Barbara — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Smither John W — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Ehrlich Christopher B — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-05-16 | 4 | Byrnes Michael — Chief Financial Officer | Grant/award (A): 4,863 @ $0.46 | EDGAR |
| 2023-05-16 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Grant/award (A): 6,401 @ $0.46 | EDGAR |
| 2023-01-24 | 4 | Harrington-Smith Kristen — Director | Grant/award (A): 28,125 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Bhatt Elizabeth — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Gallagher Brian M. Jr. — Director | Grant/award (A): 50,938 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Klencke Barbara — Director | Grant/award (A): 28,125 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Smither John W — Director | Grant/award (A): 36,875 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Ehrlich Christopher B — Director | Grant/award (A): 35,938 (derivative) @ $0 | EDGAR |
| 2023-01-19 | 4 | Warner Douglas J — Chief Medical Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2023-01-19 | 4 | Gandhi Mayank — Chief Business Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-01-19 | 4 | Byrnes Michael — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-01-19 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | Byrnes Michael — Chief Financial Officer | Grant/award (A): 4,651 @ $0.47 | EDGAR |
| 2022-11-16 | 4 | WORLAND STEPHEN T — Chief Executive Officer, Director | Grant/award (A): 6,047 @ $0.47 | EDGAR |
| 2022-10-06 | 4 | Ehrlich Christopher B — Director | Purchase (P): 346 @ $0.57 | EDGAR |
| 2022-09-28 | 4 | Gandhi Mayank — Chief Business Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-09-27 | 4 | Ehrlich Christopher B — Director | Purchase (P): 18,867 @ $0.55 | EDGAR |
| 2022-08-08 | 4 | Warner Douglas J — Chief Medical Officer | Grant/award (A): 618,160 (derivative) @ $0 | EDGAR |
| 2022-08-03 | 4 | Presidio Management Group X LLC — 10% owner US VENTURE PARTNERS X LP — 10% owner USVP X AFFILIATES LP — 10% owner Tansey Casey M — 10% owner ROOT JONATHAN D — 10% owner | Sale (S): 25,896 @ $0.79 · Sale (S): 807 @ $0.79 · Sale (S): 27,348 @ $0.80 · Sale (S): 853 @ $0.80 · Sale (S): 57,580 @ $0.80 · Sale (S): 1,796 @ $0.80 | EDGAR |
| 2022-07-29 | 4 | Presidio Management Group X LLC — 10% owner US VENTURE PARTNERS X LP — 10% owner USVP X AFFILIATES LP — 10% owner Tansey Casey M — 10% owner ROOT JONATHAN D — 10% owner | Sale (S): 31,533 @ $0.89 · Sale (S): 984 @ $0.89 | EDGAR |
| 2022-07-27 | 4 | Presidio Management Group X LLC — 10% owner US VENTURE PARTNERS X LP — 10% owner USVP X AFFILIATES LP — 10% owner Tansey Casey M — 10% owner ROOT JONATHAN D — 10% owner | Sale (S): 2,210 @ $0.93 · Sale (S): 69 @ $0.93 · Sale (S): 2,691 @ $0.90 · Sale (S): 84 @ $0.90 · Sale (S): 42,344 @ $0.89 · Sale (S): 1,321 @ $0.89 | EDGAR |
| 2022-07-22 | 4 | Presidio Management Group X LLC — 10% owner US VENTURE PARTNERS X LP — 10% owner USVP X AFFILIATES LP — 10% owner Tansey Casey M — 10% owner ROOT JONATHAN D — 10% owner | Sale (S): 9,726 @ $1.00 · Sale (S): 304 @ $1.00 · Sale (S): 2,584 @ $0.95 · Sale (S): 81 @ $0.96 · Sale (S): 7,383 @ $0.91 · Sale (S): 231 @ $0.91 | EDGAR |
Recent 8-K events — eFFECTOR Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-06-26 | 8-K | 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
| 2024-06-25 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-06-24 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-14 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-05-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-05-09 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-09 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.01 — Changes in Control of Registrant | EDGAR |
| 2024-05-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-04 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EFTR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs